盐酸曲唑酮治疗酒依赖戒断后心理及生理症状的临床研究

目的 探讨盐酸曲唑酮治疗酒依赖戒断后患者焦虑、抑郁、失眠等心理及躯体症状的有效性和安全性.方法 采用随机、双盲、安慰剂对照的方法把100例符合纳入和排除标准的患者分成盐酸曲唑酮组和安慰剂组.每个患者均口服盐酸曲唑酮或安慰剂每日3次,每次1片,疗程均为8周.于治疗后第l,2,4,8周末分别进行汉密顿焦虑量表(HAMA)、汉密顿抑郁量表(HAMD)、匹兹堡睡眠质量指数(PSQI)、副反应量表(TESS)评分.1年后调查复饮情况.结果 有81例完成治疗,19例因提前出院或失访未完成治疗脱失.盐酸曲唑酮组(41例)汉密顿焦虑量表、汉密顿抑郁量表及匹兹堡睡眠质量指数评分治疗后与治疗前比较,总分值逐渐下降,2周后上述3项评分和安慰剂组(40例)分别比较差异有显著性(P<0.05);1年后复饮率盐酸曲唑酮组(24.4%)明显低于安慰剂组(55.0%,P<0.05).治疗后两组副反应量表评分比较差异无显著性(P>0.05).结论 盐酸曲唑酮能有效改善酒依赖戒断后患者焦虑、抑郁及失眠症状,且能有效降低复饮率.

Abstract：

Objective To explore the efficacy and safety of anxiety, depression, insomnia and other psychological and physical symptoms after trazodone treated in patients with alcohol dependence. Methods 100 patients whose met the inclusion and exclusion criteria were divided into trazodone group and the placebo group with a randomized, double-blind, placebo-controlled method. Each of the patients was oral trazodone, or placebo 3 times a day, each time a course of treatment was 8 weeks. Hamilton Anxiety Scale ( HAM A) , Hamilton Depression Rating Scale(HAMD) , Pittsburgh Sleep Quality Index(PSQI) , side effects scale (TESS) score and the necessary examinations were used to assess. Survey the re-drink situation after 1 year. Results 81 patients completed treatment, 19 patients were discharged or lost due to early treatment failure loss. In Trazodone group (41 cases) , the HAMA, HAMD and PSQI score before treatment and after treatment, total scores decreased gradually after 2 weeks of the three score and comfort dose group (40 cases) were the difference was statistically significant (P< 0. 05 ) ;recovery drink rate of trazodone group was significantly lower than the placebo group (24.4% vs 55. 0% , P<0. 05) after 1 year. After treatment, the side effects scale score difference was not statistically significant (P> 0. 05 ). Conclusion Improve trazodone treat alcohol dependence withdrawal anxiety, depression and insomnia effectively. Found no adverse drug reactions and the safety is high. Reduce the recovery drink.

Observation on the efficacy and safety of physical and psychological symptoms in the inpatients with alcohol dependence after Trazodone treatment

Objective To explore the efficacy and safety of anxiety, depression, insomnia and other psychological and physical symptoms after trazodone treated in patients with alcohol dependence. Methods 100 patients whose met the inclusion and exclusion criteria were divided into trazodone group and the placebo group with a randomized, double-blind, placebo-controlled method. Each of the patients was oral trazodone, or placebo 3 times a day, each time a course of treatment was 8 weeks. Hamilton Anxiety Scale ( HAM A) , Hamilton Depression Rating Scale(HAMD) , Pittsburgh Sleep Quality Index(PSQI) , side effects scale (TESS) score and the necessary examinations were used to assess. Survey the re-drink situation after 1 year. Results 81 patients completed treatment, 19 patients were discharged or lost due to early treatment failure loss. In Trazodone group (41 cases) , the HAMA, HAMD and PSQI score before treatment and after treatment, total scores decreased gradually after 2 weeks of the three score and comfort dose group (40 cases) were the difference was statistically significant (P< 0. 05 ) ;recovery drink rate of trazodone group was significantly lower than the placebo group (24.4% vs 55. 0% , P<0. 05) after 1 year. After treatment, the side effects scale score difference was not statistically significant (P> 0. 05 ). Conclusion Improve trazodone treat alcohol dependence withdrawal anxiety, depression and insomnia effectively. Found no adverse drug reactions and the safety is high. Reduce the recovery drink.